The CANTOS trial showed that therapy with Canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, administered in patients with an earlier myocardial infarction and C-reactive protein (CRP) values of at least 2 mg/L reduced the incidence of the composite endpoint of non-fatal myocardial infarction, non-fatal stroke, and death from cardiovascular causes, but increased the risk of fatal infections [14]. This evidence concerns the gene CRP and myocardial infarction.